<DOC>
	<DOCNO>NCT02742324</DOCNO>
	<brief_summary>Phase 1/2 , open-label , multi-center , trial , aim identify efficacious dose combination also satisfy certain safety requirement . It consist dose find study ass safety combination different dos ruxolitinib peg-IFN alpha-2a , secondary randomize evaluation optimal dos find first part study total maximal number 42 evaluable patient .</brief_summary>
	<brief_title>Trial Ruxolitinib Peg-interferon Alpha-2a Combination Patients With Primary Myelofibrosis RUXOPeg</brief_title>
	<detailed_description>Part 1 dose find phase 1 trial ass safety combination different dos ruxolitinib peg-IFN alpha-2a Part 2 phase 2 randomized evaluation optimal dos find first part study total maximal number 42 evaluable patient . It use Bayesian Phase 1/2 adaptively randomized design propose Yuan Yin ( 2011 ) combine drugs.The trial examine three dos ruxolitinib : 10 , 15 20 mg BID three dose peg-IFN alpha-2a : 45 , 90 , 135 mcg/week ) . The starting dos drug select base prior monotherapy experience dose show degree clinical activity single agent pharmacodynamic data support activity observe . In interest patient safety , compound start dose level near 50 % respective maximum tolerated dos .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Patients eligible inclusion study meet follow criterion : Age &gt; 18 year &lt; 66 year Diagnosis primary secondary myelofibrosis accord 2008 World Health Organization ( WHO ) criterion PMF ( Tefferi Vardiman 2008 ) propose criterion PPVMF PETMF outline International Working Group Myelofibrosis Research Treatment ( Barosi et al 2008 ) Patients classified high risk , OR intermediate risk2 , OR intermediate risk1 , define International Working Group , IWG ( Cervantes , et al 2009 ) diagnosis ( DIPSS ( Passamonti et al . 2010 ) patient assessed diagnosis PMF ) Need active therapy , define presence least one following : symptomatic splenomegaly presence constitutional symptom anemia ( Hb &lt; 10g/dl ) leukocytosis &gt; 25 G/l thrombocytosis &gt; 400 G/l Presence JAK2V617F , Calreticulin MPL mutation Platelet count ≥ 150 x 109/L reach aide transfusion screen Patients ANC ≥ 1.5 x 109/L screen without use GCSF Peripheral blood blast count ≤ 10 % Screening ECOG performance status 0 , 1 , 2 Screening Negative serological Hepatitis B test ( i.e . HBsAg negative antiHBc negative , patient positive antiHBc may include PCR HBV DNA negative ) ; negative test Hepatitis C RNA ; negative HIV test within 6 week prior registration . Women childbearing potential must negative serum ( betahuman chorionic gonadotropin [ betahCG ] ) urine pregnancy test Screening effective contraception 's method study 75 day last dose . Informed consent sign Patients without Social Security coverage Patient include another clinical study 1 month end study ANC &lt; 1.5 G/l platelet &lt; 150 G/l &gt; 10 % circulate blast Contraindication IFN alpha ruxolitinib Patients previously treat IFN alpha JAK2 inhibitor Documented autoimmune disease screen medical history History presence depression require treatment antidepressant Evidence severe retinopathy ( e.g . cytomegalovirus retinitis , macular degeneration ) clinically relevant ophthalmological disorder ( due diabetes mellitus hypertension ) Thyroid dysfunction adequately control Women childbearing potential positive serum pregnancy test screen wish use effective method contraception , treatment 75 day last dose study drug . Pregnant nursing ( lactate ) woman Patients know active hepatitis B C know HIV positivity Patient concurrent malignancy malignancy within 3 year Screening , exception adequately treat basal squamous cell carcinoma , non melanomatous skin cancer curatively resect cervical cancer . Patient history cardiac dysfunction include follow : Myocardial infarction document elevated cardiac enzyme persistent regional wall abnormality assessment LVEF function History document congestive heart failure ( New York Heart Association functional classification IIIIV ) Documented cardiomyopathy Patient active cardiac disease include follow : Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % determined Multiple Gated Acquisition ( MUGA ) echocardiogram ( ECHO ) QTc &gt; 480 msec screen ECG ( QTcF , use Fridericia formula ) Angina pectoris require use antianginal medication Ventricular arrhythmia except benign premature ventricular contraction Supraventricular nodal arrhythmia require pacemaker control medication Conduction abnormality require pacemaker Valvular disease document compromise cardiac function Symptomatic pericarditis Patients inadequate liver renal function Screening demonstrate : encephalopathy grade 1 , per West Haven Criteria know hepatocellular disease ( e.g . active hepatitis cirrhosis ) total bilirubin &gt; 2 x ULN subsequent determination direct bilirubin &gt; 2 x ULN alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 x ULN MDRDeGFR &lt; 45 mL/min/1.73m2 dialysis Patients currently willing candidate stem cell transplantation time screen assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>